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The first described patients with pyridox(am)ine 5’-phosphate oxidase deficiency all had neonatal onset seizures that did not
respond to treatment with pyridoxine but responded to treatment with pyridoxal 5’-phosphate. Our data suggest, however, that
the clinical spectrum of pyridox(am)ine 5’-phosphate oxidase deficiency is much broader than has been reported in the literature.
Sequencing of the PNPO gene was undertaken for a cohort of 82 individuals who had shown a reduction in frequency and
severity of seizures in response to pyridoxine or pyridoxal 5’-phosphate. Novel sequence changes were studied using a new cell-
free expression system and a mass spectrometry-based assay for pyridoxamine phosphate oxidase. Three groups of patients with
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PNPO mutations that had reduced enzyme activity were identified: (i) patients with neonatal onset seizures responding to
pyridoxal 5’-phosphate (n = 6); (ii) a patient with infantile spasms (onset 5 months) responsive to pyridoxal 5’-phosphate
(n = 1); and (iii) patients with seizures starting under 3 months of age responding to pyridoxine (n = 8). Data suggest that
certain genotypes (R225H/C and D33V) are more likely to result in seizures that to respond to treatment with pyridoxine. Other
mutations seem to be associated with infertility, miscarriage and prematurity. However, the situation is clearly complex with the
same combination of mutations being seen in patients who responded and did not respond to pyridoxine. It is possible that
pyridoxine responsiveness in PNPO deficiency is affected by prematurity and age at the time of the therapeutic trial. Other
additional factors that are likely to influence treatment response and outcome include riboflavin status and how well the foetus
has been supplied with vitamin B6 by the mother. For some patients there was a worsening of symptoms on changing from
pyridoxine to pyridoxal 5’-phosphate. Many of the mutations in PNPO affected residues involved in binding flavin mononucleo-
tide or pyridoxal 5’-phosphate and many of them showed residual enzyme activity. One sequence change (R116Q), predicted to
affect flavin mononucleotide binding and binding of the two PNPO dimers, and with high residual activity was found in Groups
(ii) and (iii). This sequence change has been reported in the 1000 Genomes project suggesting it could be a polymorphism but
alternatively it could be a common mutation, perhaps responsible for the susceptibility locus for genetic generalized epilepsy on
17q21.32 (close to rs72823592). We believe the reduction in PNPO activity and B6-responsive epilepsy in the patients reported
here indicates that it contributes to the pathogenesis of epilepsy.
Keywords: pyridoxal 5’-phosphate (PLP); pyridoxine; pyridox(am)ine 5’-phosphate oxidase (PNPO); seizures; epilepsy
Abbreviations: FMN = flavin mononucleotide; PLP = pyridoxal 5’-phosphate; PMP = pyridoxamine phosphate
Introduction
Pyridox(am)ine phosphate oxidase (PNPO, EC 1.4.3.5) is a flavin
mononucleotide (FMN)-dependent oxidase required for synthesis
of pyridoxal 5’-phosphate (PLP) from pyridoxine (and its phos-
phate, PNP, and glucoside) and from pyridoxamine (and its phos-
phate, PMP) in the diet. It is also required for recycling PMP to
regenerate PLP, the active cofactor. PLP is the cofactor for 4140
enzyme-catalyzed reactions in man, including many involved in
synthesis or degradation of amino acids or amines that serve as
neurotransmitters or neuromodulators in the brain (Garcia-Cazorla
et al., 2012; Mills et al., 2012).
Neonatal epileptic encephalopathy is characterized by the onset,
shortly after birth, of drug-resistant seizures associated with severe
neurological dysfunction that can be fatal. PNPO deficiency
(OMIM 6032870) is an autosomal recessive inborn error of me-
tabolism that leads to a seizure disorder, presenting in the new-
born period (neonatal epileptic encephalopathy) or early infancy,
that can be treated with pyridoxal 5’-phosphate but (classically)
not pyridoxine. Mills et al. (2005) showed that mutations in PNPO
led to reduced enzyme activity when expressed in Chinese ham-
ster ovary cells.
A review by Garcia-Cazorla et al. (2012) of 16 cases with PNPO
deficiency (eight families) revealed that clinical features included in
utero seizures, 3/16; foetal distress before delivery, 5/16; prema-
ture birth, mean 32 weeks gestation; low Apgar scores/requiring
intubation at delivery, 5/16; onset of seizures—in first 24 h, 11/
14; between 24 h and 72 h, 2/14; between 72 h and 2 weeks 1/
14; burst suppression pattern on EEG, 10/11; seizures completely
resistant to antiepileptic drugs, 13/16; completely resistant to pyri-
doxine, 7/10; metabolic acidosis 6/16; raised blood lactate 8/16;
distressing spasms (dystonia), 3/16; anaemia, 3/16; hepatomeg-
aly, 3/16; abdominal distension, 2/16; and hypoglycaemia 2/16.
In the small number of patients tested, CSF PLP concentration was
low (Ormazabal et al., 2008). However, other disorders can also
lead to low CSF PLP (Footitt et al., 2011).
In addition to the small number of infants in the literature
whose PLP-responsive neonatal epileptic encephalopathy has
been shown to be a result of PNPO deficiency, a larger number
of infants has been described for whom empirical clinical trials
demonstrated that their severe epilepsy was better controlled
with PLP than with pyridoxine (Wang et al., 2005). This suggests
that PNPO deficiency might be a cause, not only of neonatal
epileptic encephalopathy, but also of other later-onset seizure
disorders.
A genome-wide association study of patients of European an-
cestry identified an important susceptibility locus for genetic gen-
eralized epilepsies as a whole at 17q21.32 (rs72823592), the
closest gene to which is PNPO (EPICURE Consortium et al.,
2012). This data suggests that mild PNPO deficiency could be a
susceptibility factor for genetic generalized epilepsies presenting at
various ages.
Mutations in PNPO known to be associated with neonatal epi-
leptic encephalopathy for which expression studies have shown
reduced enzyme activity are: IVS3-1g4a, X262Q, R229W (Mills
et al., 2005) and R95H (Khayat et al., 2008). Other probable
neonatal epileptic encephalopathy-causing PNPO mutations in-
clude R95C, D33V, c.246delT (Hoffmann et al., 2007), A174X
(Ruiz et al., 2008), R225C (Veerapandiyan et al., 2011) and
G118R (Pearl et al., 2012).
The effects of R229W on PNPO catalytic function and crystal
structure have been studied by Musayev et al. (2009). This variant
is 850-fold less efficient than the wild-type enzyme because of a
192-fold decrease in pyridoxine 5’-phosphate affinity and a 4.5-
fold decrease in catalytic activity. There is also a 50-fold reduction
in affinity for the FMN cofactor. The decrease in affinity for
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pyridoxine 5’-phosphate suggests that, for this mutation, signifi-
cantly increased synthesis of PLP might be achieved by high dose
pyridoxine. In fact, in the premature infants affected by the
R229W mutation, administration of pyridoxine did lead to partial
improvement in clonic contractions and lip-smacking automatisms;
in contrast, patients harbouring mutations with no residual activity
showed no response to pyridoxine. Musayev et al. (2009) sug-
gested that, for the R229W mutation at least, another treatment
likely to be beneficial would be riboflavin, which would supply
extra FMN and partially overcome the effect of reduced FMN
binding.
Thus, a picture is emerging of PNPO sequence variations that
produce epilepsy that only responds to treatment with PLP,
through variations that may respond to pyridoxine and/or ribofla-
vin to PNPO variations that might be insufficient to produce epi-
lepsy alone but might do so in concert with other factors
determining brain PLP levels such as genes influencing blood
PLP levels [e.g. the TNSALP gene (now known as ALPL) encoding
tissue non-specific alkaline phosphatase (Hazra et al., 2009;
Tanaka et al., 2009)] and dietary intakes of B6 vitamers and
riboflavin.
In this study we looked for PNPO sequence variations in chil-
dren with epilepsy that responded to treatment with pyridoxine or
PLP. We characterized the phenotypic spectrum of PNPO defi-
ciency further and demonstrated that some children with PNPO
deficiency respond to treatment with pyridoxine. To determine the
effect of sequence variations on PNPO enzyme activity we set up
a new, cell-free system for expression of the mutant proteins and
a new mass spectrometry-based enzyme assay for measurement
of PNPO activity.
Materials and methods
Patients
This study was approved by the Ethics Committee of UCL Institute of
Child Health and Great Ormond Street Hospital (04/Q0508/81).
Patients included satisfied the following criteria: (i) improved seizure
control following administration of pyridoxine or PLP; and (ii) exclusion
of antiquitin deficiency by measurement of urinary -aminoadipic
semialdehyde and/or sequencing of ALDH7A1 (Mills et al., 2010).
Detailed histories and the questionnaire sent to clinicians are available
in the Supplementary material.
Chemical reagents
All chemicals unless mentioned specifically were from Sigma Aldrich.
D2 PLP was kindly supplied by Professor Coburn, Department of
Chemistry, Indiana University-Purdue University, Fort Wayne,
Indiana, USA.
PNPO sequencing
Mutation analysis of genomic DNA and complementary DNA was as
described previously (Mills et al., 2005).
Site-directed mutagenesis of PNPO and
expression studies
Wild-type PNPO complementary DNA had been cloned into pSP72
previously (Mills et al., 2005). Site-directed mutagenesis was carried
out using the QuikChange XL Site-Directed Mutagenesis Kit
(Stratagene), according to manufacturer’s instructions. The comple-
mentary DNA was then amplified using ProofStartTM DNA polymerase
(Qiagen) using primers detailed in Supplementary Table 1. EcoRI di-
gestion products were subcloned into the pT7CFE1-CHis expression
vector (Thermo Scientific). PNPO was expressed using the Thermo
Scientific 1-Step Human Coupled IVT Kit according to manufacturer’s
instructions; this expression system uses a HeLa cell lysate. The reac-
tion was incubated for 6 h at 30C. PNPO enzyme activity was mea-
sured with PMP as substrate. Expressed protein (8 ml) was incubated at
37C in the dark in 20 mM potassium phosphate (pH 7.6) containing
2.5 mM PMP and 1.5 mM FMN in a final volume of 120 ml. The reaction
was stopped by addition of 120ml 0.3 N trichloroacetic acid containing
d2-PLP and incubated on ice for 30 min before centrifugation
(10 000 rpm, 10 min at 4C). The supernatant containing the B6 vita-
mers was analysed by HPLC-MS/MS (Footitt et al., 2013). Enzyme
activity was calculated as pmol PLP synthesized/mg protein/min and
expressed as a percentage of the activity obtained with the wild-type
enzyme.
Results
Mutations
Sequencing of the PNPO gene was undertaken for 82 individuals
that had shown some reduction in frequency and severity of seiz-
ures in response to pyridoxine or PLP. Mutations were identified in
PNPO for 15 patients (Table 1) from 14 families. Five of these
were novel; three missense mutations and two deletions/inser-
tions. The novel missense mutations E120K, P213S and R225H
have not been reported as polymorphisms in Ensembl (http://
www.ensembl.org). All novel missense mutations were tested for
pathogenicity using both SIFT (Sim et al., 2012) and the PolyPhen
web server (Ramensky et al. 2002) and were predicted to be
damaging or probably damaging, respectively (Supplementary
Table 2).
Previously reported mutations included D33V, R95H, R95C and
R225C. E50K, which has been reported as a single nucleotide
polymorphism (Mills et al., 2005), was detected in Patient 1.
The sequence variant R116Q (rs 17679445) was detected in 5
of 15 patients. This is reported on Ensembl as a single nucleotide
polymorphism in the majority of populations with the exception of
individuals of Asian ancestry (Supplementary Table 3) with a
prevalence of 4–10% depending on the subpopulation investi-
gated. R116Q was found in some patients in combination with
other mutations that we believe are pathogenic and which have
not been reported previously in the general population. However,
R116Q was the only sequence change detected in Patients 7 and
8. Comparison of the frequency of R116Q in our PNPO-deficient
patients relative to 1000 Genomes allele frequencies (http://www.
ensembl.org) suggests that R116Q is over-represented in our
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patients compared to the general population (Supplementary
Table 3).
Clinical phenotypes
Our series of PNPO patients has identified some new clinical pres-
entations, including seizures with onset under 3 months responsive
to treatment with pyridoxine and seizures with onset after 3
months responsive to PLP, suggesting that the phenotype of this
disorder is much broader than reported previously. Patient clinical
features are summarized in Table 2 and individual histories are
given in the Supplementary material.
Five patients were identified with neonatal onset seizures re-
sponsive to PLP and one affected sibling was treated prophylac-
tically, in utero and from birth (Patient 4). Immediate seizure
control was seen upon administration of PLP in three of five of
these patients and seizure control was achieved in Patients 6 and 3
after treatment with PLP for 12 h and 3 days, respectively. Patient
7 did not present with seizures until 5 months of age. Initial doses
of PLP ranged from 10–85 mg/kg/day and maintenance doses
range from 10–72 mg/kg/day. Individual treatment regimes are
detailed in the Supplementary material.
To our surprise, 62% of patients in this series that had an onset
of seizures under 3 months showed a dramatic response to
treatment with pyridoxine (Patients 8–15); initial and maintenance
doses ranging from 18–55 and 6–26 mg/kg/day, respectively.
Reported seizure types (Table 2) included clonic (45%), myo-
clonic jerks (55%), tonic (30%), generalized tonic-clonic (79%)
and focal (45%). EEG abnormalities included burst suppression
and hypsarrhythmia (Table 2, Supplementary material). A cranial
ultrasound at 5 h showed bilateral grade 3 intraventricular haem-
orrhages with associated moderate ventricular dilatation in one
patient. The MRI findings (Supplementary material) varied from
normal to extensive white matter oedema and a possible haem-
orrhage and changes reported as consistent with hypoxic ischae-
mic encephalopathy. Two patients on PLP treatment have
persistently deranged liver function tests.
Expression studies
In vitro expression studies using the HeLa cell lysate system
showed that wild-type PNPO activity was readily measurable.
Several PNPO sequence variants that had been expressed previ-
ously using the Chinese hamster ovary cell system (R229W,
X262Q and E50K) (Mills et al., 2005) were investigated using
this more rapid approach so that we could compare the two
expression systems. Using this new system we investigated the
effects of R116Q on PNPO activity to determine if the single
Table 1 Summary of mutations/sequence variants found in PNPO that have an effect on PNPO enzyme activity
Group Patient Current
age
Mutation/sequence variant Presumed effect Age of
seizure
onset
References
(i) 1 4 y c.[284G4A] (M) + c.[148G4
A];c.[364-1G4A]a (P)
p.R95H (M) + p.E50K;Splice
errors a (P)
30 min Mills et al., 2005; Khayat
et al., 2008
2 5 y 2 m c.[98A4T] + c.[98A4T] p.D33V + p.D33V 6 h Hoffmann et al., 2007
3 2 y 7 m c.[637C4T] + c.[637C4T] p.P213S + p.P213S 90 min Novel
4* 4 m c.[637C4T] + c.[637C4T] p.P213S + p.P213S None* Novel
5 1 y c.[283C4T] (M) + c.[283C4T] (P) p.R95C (M) + p.R95C (P) 2 h Khayat et al., 2008
6 4 y c.[641dupA] + ?** p.Q214fs + ? ** 5 h Novel
(ii) 7 6 y 5 m c.[347G4A] (M) + c.[347G4A] (P) p.R116Q (M) + p.R116Q (P) 5 m Novel
(iii) 8 9 y c.[347G4A] + c.[347G4A] p.R116Q + p.R116Q 3 h Novel
9 2 y c.[98A4T] + c.[998A4T] p.D33V + p.D33V 3 w Hoffmann et al., 2007
10 23 y c.[98A4T] + c.[358G4A] p.D33V + p.E120K 2 m Hoffmann et al.,
2007 + novel
11 21 y c.[98A4T] (P) + c.264-21_
264-1delinsC (M)
p.D33V (P) + Splice errors (M) 3 h Hoffmann et al.,
2007 + novel
12 41 y c.[98A4T] + c.[347G4A] +
c. [673C4T]
p.D33V + p.R116Q + p.R225Cb 14 d Hoffmann et al.,
2007 + novel + Veera-
pandiyan et al., 2011
13 9 y c.[674G4A] + c.[674G4A] p.R225H + p.R225H 24 h Novel
14 3 y c.[347G4A];c.[674G4A] + c.[347G
4A];c.[674G4A]
p.R116Q;p.R225H +
p.R116Q;p.R225H c
30 min Novel
15 9 y c.[347G4A];c.[674G4A] + c.[347G
4A];c.[674G4A]
p.R116Q;p.R225H +
p.R116Q;p.R225H c
10 h Novel
(i) Neonatal onset seizures responding to pyridoxal 5’-phosphate;
(ii) Infantile spasms (onset 5 months) responsive to pyridoxal 5’-phosphate;
(iii) Seizures starting under 3 months of age responding to pyridoxine.
Where parent DNA available inheritance was investigated and the allele carrying the mutation is indicated as P (paternal) or M (maternal).
*Sibling of Patient 3, no seizures as treated prophylactically;
**Second mutation not found, complementary DNA and genomic DNA sequenced;
ac.[148G4A] and c.[364-1G4A] were inherited in cis, this was confirmed by analysing parental DNA;
b No parental DNA was available to ascertain which muation R116Q was in cis with;
cAssume that R116Q has been inherited in cis with R225H, no parental DNA was available to confirm this.
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nucleotide polymorphism is ‘possibly damaging’ as predicted by
PolyPhen, or ‘tolerated’ as predicted by SIFT (Supplementary
Table 2). The effects of R225H, R225C and D33V were also stu-
died in more detail as these sequence variants had been found in
various combinations with R116Q.
Characterization of wild-type PNPO activity and the various
mutant constructs revealed a pre-steady state period where the
rate of PLP synthesis was slower than that seen between 10–
20 min. This was true for all constructs investigated and was also
apparent when PNPO was overexpressed in Chinese hamster
ovary cells previously (unpublished data).
Figure 1 shows that the presence of R229W, X262Q, R225H
and R225C led to a reduction in PLP synthesis to 8–15% of the
rate catalyzed by wild-type PNPO. The effect of D33V on PNPO
activity was less dramatic with 45% PNPO activity being
retained. E50K, which had no effect on PNPO activity when over-
expressed in Chinese hamster ovary cells, resulted in decreased
PNPO activity by 25% when compared to wild-type activity
whereas the presence of R116Q decreased PNPO activity by
17%.
Discussion
Mutations
This article takes the number of published disease-causing muta-
tions in PNPO to 14. However, if we include sequence variants
reported previously to be single nucleotide polymorphisms and
shown here to result in reduced PNPO activity i.e. E50K and
Table 2 Demographic, clinical and electroencephalographic features observed in the present series with PNPO deficiency
Clinical features and demographics Incidence
Gender Male n = 9; female n = 6
Ethnicity Caucasian n = 10; Turkish n = 1; Asian (British) n = 1; Kosovan n = 1;
Pakastani n = 1; Unknown n = 1
Parental consanguinity 3/11 (27%)
Family history of infertility / foetal loss 4/12 (25%)
Gestational age4 37/40 6/13 (46%)
Abnormal intrauterine movements 3/11 (27%)
Foetal distress 4/11 (36%)
Apgar score 57 at 1 min 2/11 (18%)
Acidosis 5/10 (50%)
Respiratory distress 4/11 (36%)
Hypotonia (neonatal) 6/10 (60%)
Abdominal distension / vomiting 1/7 (14%)
Irritability 4/10 (40%)
Seizure onset within first 28 days 12/14 (86%)
Resistance to antiepileptic drugs Complete: 8/14 (57%); partial: 6/14 (43%)
EEG Burst suppression: 6/11 (55%); Hypsarrhythmia: 1/11 (9%); Otherc: 4/
11 (36%)
Seizure type: clonic 5/11 (45%)
Seizure type: tonic 3/10 (30%)
Seizure type: generalized tonic-clonic 11/14 (79%)
Seizure type: myoclonic jerks 6/11 (55%)
Seizure type: focal 5/11 (45%)
Response to pyridoxine 8/13 (62%)
Worsening of seizures upon change from PN to PLP 3/8 (38%)
Trial of PLPa 10/15 (67%)
Response to PLP trial Immediate: 6/10 (60%); within 12 h to 3 days: 2/10 (20%)
Trial of PLP withdrawalb 5/7 (71%)
Speech delay 8/13 (62%)
Motor delay Marked: 3/12 (33%); Minimal: 3/12 (17%); None: 6/12 (50)%
Breakthrough seizures with fever 6/12 (50%)
Observed in the present series but not previously described in clinically diagnosed PNPO deficiency
Severe neuropathy with persistent loss of ankle jerks (75 mg
TDS PN)
1 patient
Gut perforation and septicaemia 1 patient
Liver function abnormalities 2 patients
aOne patient treated prophylactically.
bEither planned, accidental or reduced dose/kg due to age.
cIncluded suppression rhythms over right mid-temporal zone and focal seizures (bilateral, independent) for one patient and generalized suppressions and sharp wave
complexes over both hemispheres for another. Where the incidence denominator is 515 the information was not completed/available for the patient in the proforma
returned by the treating clinician.
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R116Q, this number rises to 16. Although some mutations are
‘private’, D33V, R95H/C and R225H/C appear common; being
responsible for 15%, 23% and 14% of mutated alleles, respect-
ively. Whilst the novel missense mutations P213S and E120K
affect residues conserved across mammalian species, as do the
sequence variants E50K and R116Q (Supplementary Fig. 1),
R225H and R225C affect a residue conserved not only across
mammalian species but also across fish and lower organisms
(Supplementary Fig. 2). The novel 21-base deletion/single base
insertion (c.264-21_264-1delinsC) is predicted to result in skipping
of Exon 3. If translated this would cause a frameshift in the protein
sequence after T87, altering the next 25 amino acids before intro-
ducing an early stop codon. Unfortunately no complementary
DNA was available for confirmation. The insertion of a single nu-
cleotide in exon 7 (c.641dupA) is predicted to cause a change in
the amino acid sequence and an early stop codon.
Expression studies
Characterization of the PNPO wild-type and mutant proteins re-
vealed a slower pre-steady state period (Fig. 1A). Ordinarily
transient periods in enzyme catalyzed reactions only occur for a
few seconds whilst the enzyme and substrate form a complex,
however, the lag period here persisted for the first 5 min. PNPO
has been shown to be a sluggish enzyme with a turnover number
of only 0.19/s and 0.20/s for PNP and PMP, respectively and it is
self-regulated by its product PLP (Musayev et al., 2003). PNPO is
a dimeric enzyme that contains a non-catalytic site on each of the
monomers that binds PLP tightly (Safo et al., 2005).
Crystallographic studies suggested that a tunnel may exist be-
tween the active site and this secondary non-catalytic site acting
to protect PLP from nucleophiles and channelling it to vitamin B6
apoenzymes (Safo et al., 2005). If the endogenous PLP in the cell
free expression system (Time 0; Fig. 1A) is bound at the non-
catalytic site, the active site would be open and the enzyme re-
action would proceed with steady-state kinetics. However, if the
endogenous PLP is tightly bound at the active site in the closed
position, the substrate PMP would have to bind at an allosteric site
to enable a conformational change to occur. This would allow the
tightly bound PLP at the active site to be released and catalysis to
proceed (Safo et al., 2005). This may explain the slower rate of
reaction observed initially.
Comparison of PNPO activity for two mutations that have been
over-expressed previously in Chinese hamster ovary cells, i.e.
R229W and X262Q, to that obtained using the new more rapid
cell-free expression system confirmed that these sequence variants
are pathogenic. Previously these mutations produced 30% and
undetectable PNPO activity, respectively (Mills et al., 2005)
whereas in the new system these mutations resulted in 15%
and 12% residual activity, respectively. The discrepancy between
these two systems is perhaps not surprising; the LC-MS/MS based
system is more sensitive than the spectrophotometric assay and
also allows for PLP product inhibition. E50K which had previously
been shown to have no effect on PNPO activity when over-ex-
pressed in Chinese hamster ovary cells (Mills et al., 2005), did
have 30% lower activity than wild-type. E50K has been identified
(previously and in Patient 1) in cis with the splice site mutation
c.364-1G4A (IVS3-1g4a). Previous expression studies concluded
that c.364-1G4A is a pathogenic mutation (Mills et al., 2005)
and that E50K was a polymorphism. E50 is conserved across mam-
malian species (Supplementary Fig. 2) and is predicted by SIFT and
PolyPhen to have a ‘damaging effect’ and to be ‘probably dama-
ging’ to protein activity, respectively (Supplementary Table 2).
Whether this sequence variant—on its own or in combination
with environmental factors—would prove sufficient to result in
B6-responsive epilepsy remains to be seen.
The effects of R225H, R225C and D33V on PNPO activity were
also investigated as these sequence variants were found in various
combinations with R116Q. Expression of R225H and R225C dra-
matically reduced PNPO activity to 9% and 8% of wild-type ac-
tivity, respectively (Fig. 1). The effect of D33V on PNPO activity
was investigated as Kang et al., (2004) reported that deletion of
the first 56 N-terminal amino acid residues of human PNPO af-
fected neither binding of coenzyme nor catalytic activity. In our
expression system D33V dramatically reduced enzyme activity by
60%. This was not surprising as D33V accounts for 15% of
sequence changes found in PNPO patients to date. We conclude
therefore that D33V is pathogenic.
Figure 1 (A) PNPO activity (conversion of PMP to PLP) was
measured by LC MS/MS and activity expressed as pmol PLP/mg
protein. (B) Amount of PLP synthesized over a 40-min period by
PNPO containing various mutations/sequence variants was
compared with that of wild-type PNPO.
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The presence of R116Q decreased PNPO activity by 20%
when compared with wild-type (Fig. 1). R116 is not only con-
served in mammals but also in Escherichia coli (Supplementary
Fig. 2). This residue contributes to one of two pairs of intersubunit
salt-bridges binding the two monomeric PNPO subunits to consti-
tute the functional dimer (Musayev et al., 2003). R116Q is also
predicted to affect FMN binding. The prevalence of this sequence
change within populations suggests that this polymorphism might
be a common contributor or susceptibility allele to epilepsy that
responds to treatment with PLP. R225H, R225C and D33V were
present in tandem with R116Q in Patients 12, 14 and 15.
We have yet to study these combinations. When two mutations
occur in cis in the same allele in cystic fibrosis the combination
may either improve or exacerbate the phenotype (Polizzi et al.,
2011).
Clinical phenotype
Our data suggest that the clinical spectrum of PNPO deficiency is
much broader than has been reported. The first described patients
did not respond to treatment with pyridoxine; cessation of seizures
only occurred with PLP. Recently, however, Pearl et al. (2012)
reported a patient with PNPO mutations who showed a transient
response to pyridoxine. Three groups of patients could be identi-
fied in this study with regard to their response to treatment: (i)
patients that had neonatal onset seizures responding to treatment
with PLP (n = 6); (ii) one child with infantile spasms (onset 5
months) responsive to PLP; and (iii) patients with seizures that
responded to pyridoxine (n = 8). Patient 11, from Group (iii),
had improved seizure control with a switch from pyridoxine to
PLP treatment at the age of 19 years. However, for three patients
in this group symptoms deteriorated with this change in treat-
ment. The worsening of seizure control with attempting to
switch to PLP therapy is noteworthy. High doses of PLP can
cause seizures in experimental animals and in infants (Ishioka
et al., 1995; Hammen et al., 1998). PNPO plays a role in control-
ling intracellular PLP levels through inhibition of the enzyme ac-
tivity by high concentrations of PLP. It is possible that a mutant
enzyme with residual activity could show impaired inhibition by
PLP thus increasing the risk of development of toxic levels.
Alternatively, it may be the build-up of another metabolite e.g.
PMP that has an adverse effect on some patients on PLP
treatment.
Patient 12 in Group (iii), at the age of 19 years, found that a
regular morning aura could be prevented by taking a multivitamin
preparation in addition to pyridoxine. The tablet contains 100 mg
riboflavin (precursor of FMN, the cofactor for PNPO) and it is
possible that this boosted residual PNPO activity. Patients 12
and 14 in Group (iii) had autistic features.
Patient 10, being treated with pyridoxine, developed a severe
neuropathy with persistent loss of ankle jerks. This is the first pa-
tient with PNPO deficiency that we have encountered to develop
a severe neuropathy. Neuropathy is well recognized in normal
adults taking doses 4200 mg/day of pyridoxine and we see it in
some patients with antiquitin deficiency on similar doses. Analysis
of plasma B6 vitamer levels in two antiquitin-deficient patients
treated with pyridoxine and showing mild peripheral neuropathy,
revealed that plasma PLP remained low whereas pyridoxal, pyri-
doxamine, PMP and pyridoxine were increased (Footitt et al.,
2013). Animal experiments have suggested that pyridoxine may
be more toxic to the PNS than other B6 vitamers (Levine et al.,
2004).
Two patients in this series that are treated with PLP have per-
sistently deranged liver function tests. Similar findings have been
documented in a child with PNPO deficiency receiving a high dose
(100 mg/kg/day) PLP treatment (Mills et al., 2012). A liver biopsy
showed early cirrhosis, which was attributed to the PLP therapy.
The PLP dose has now been reduced to 60 mg/kg/day and al-
though the liver function tests have improved, they have not
normalized and there is persistent evidence of hepatic fibrosis
and portal hypertension. Liver toxicity secondary to high dose
PLP (1000 mg/day) has also been reported for a child with homo-
cystinuria (Yoshida et al., 1985). It is uncertain whether the cause
of this toxicity is directly due to the high dose PLP or to degrad-
ation products of PLP that may form by photochemical reactions.
Liver function should be monitored in all children treated with high
doses of PLP.
Premature delivery (537/40) has been documented in the
majority of genetically confirmed PNPO-deficient cases reported
in the literature with many patients also having low Apgar scores
at delivery (often requiring intubation). In this series 54% of
the patients were born at term and, although two patients
required assistance with breathing (continuous positive airway
pressure/mechanical ventilation) and one patient required
resuscitation, most of the patients were in good condition at
birth.
In the majority of reported cases, seizures commenced within
the first hours of life. While seizures commenced in 10/14 of the
individuals reported here at 524 h, three patients did not present
with seizures until later (2, 3 and 8 weeks old, respectively) and
Patient 7 did not present until 5 months of age (Table 3). Patient 7
remains seizure-free on a dose of PLP of 10 mg/kg/day; most of
the other patients treated with PLP have required 2–10 times this
dose.
A history of infertility should alert the clinician to a possible
diagnosis of PNPO deficiency as heterozygous couples seem to
have reduced rates of conception. Four of eight families reported
previously have undergone several attempts at in vitro fertilization
treatment and/or suffered early pregnancy losses. In this study
four families reported miscarriages, treatment for infertility and/
or a molar pregnancy.
As with many rare diseases, it is difficult to draw conclusions
about the long-term outcome. If untreated, PNPO deficiency is
usually fatal with a single child surviving with severe epilepsy
and psychomotor delay to 3 years of age (Hoffmann et al.,
2007). In the seven cases where treatment with PLP was initiated,
only one child died and this was as a result of fungal sepsis (Ruiz
et al., 2008). The other six survived with varying degrees of dis-
ability. Here 3 of 12 patients have marked motor delay; for
Patients 11 and 13 this may relate to the duration of poor seizure
control. Six of twelve patients show no evidence of any disability.
Three patients reported here are now older than 21 years and the
eldest patient is 41 and his neurological abnormalities are limited
to dyslexia and Asperger’s syndrome.
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Influence of environmental factors
on phenotypes of individuals with
identical or similar genotypes
D33V: a predominantly pyridoxine responsive
genotype?
The response of Patients 8–15 to pyridoxine suggests that they
have sufficient enzyme activity to allow synthesis of PLP from
pyridoxine. Within this group, the missense mutation D33V was
common. Expression studies showed that D33V did not totally
abolish PNPO activity (44% residual activity). The response to
treatment with pyridoxine is therefore perhaps not surprising.
However, D33V was also found in Patient 2 whose seizures
showed no response to pyridoxine. The situation is obviously com-
plex. It is possible that pyridoxine responsiveness in PNPO defi-
ciency is affected by prematurity and age and riboflavin status at
the time of the therapeutic trial. Patient 9 (homozygous for D33V)
responded to treatment with pyridoxine and was born at term,
formula fed and tested for pyridoxine responsiveness at 3 weeks
of age. Patient 10 (compound heterozygote for D33V and E120K)
who showed a good response to pyridoxine (started at 6 months)
in terms of both seizure control and psychomotor development
and did not develop seizures until after the neonatal period (2
months). Patient 11 (compound heterozygote for D33V and
c.264-21_264-1delinsC) resembled Patient 10 with regard to
treatment response but differed in terms of neuropsychological
outcome. Perhaps the poorer outcome in Patient 11 relates to
the poorly controlled seizures in the first 2 months of life (Jonas
et al., 2005). Seizures in Patient 12 (D33V in combination with
R116Q and R225C) also responded well to treatment with pyri-
doxine. Conversely seizures in Patient 2 (homozygous D33V)
failed to respond to a 10-day trial of 100 mg pyridoxine/day
and previously reported patients [Patient 4; homozygous D33V
(Goyal et al., 2013) and Patient 3; heterozygous D33V/heterozy-
gous c.246delT (Hoffmann et al., 2007)] failed to respond to
shorter trials of pyridoxine. Perhaps Patient 2 did not respond to
pyridoxine because she was breast fed; breast feeding can be
associated with a relative deficiency of riboflavin (Hovi et al.,
1979) or perhaps because she has a second genetic factor com-
promising PLP homeostasis or neurotransmitter metabolism.
R225H/C genotype: a pyridoxine responsive
phenotype?
Patients 14 and 15 had the same sequence variants (homozygous
for R225H + R116Q) strongly suggesting that this is a pyridoxine-
responsive genotype. Patient 13 (homozygous for R225H) also
responded to treatment with pyridoxine, as did Patient 12 who
was heterozygous for R225C. Expression of R225H and R225C
revealed 8% residual activity—presumably sufficient to allow syn-
thesis of PLP from pyridoxine. Further work is required to deter-
mine whether, in the R225H/C variants, pyridoxine phosphate
oxidase activity is better preserved than pyridoxamine phosphate
oxidase activity. These enzyme activities can be differentially af-
fected by inhibitors (Takeuchi et al., 1985).
R95H, R95C and E50K with c.[364-1G4A]: alleles
associated with infertility, miscarriage, premature
birth and PLP-responsive seizures
Patient 1 was compound heterozygous for E50K plus c.[364-1G4A]
on the paternal allele and R95H on the maternal allele.
Homozygosity for E50K plus c.[364-1G4A] produced a similar clin-
ical picture (parental infertility, premature birth and PLP-responsive-
ness) in two siblings (Mills et al., 2005). Patient 5 (homozygous for
R95C) was premature and PLP-responsive and his parents had a
history of miscarriage. An infant born at 36 weeks gestation with
R95H/R95H in another series had severe neonatal epileptic enceph-
alopathy with a brief, incomplete response to pyridoxine but still a
fatal outcome (Khayat et al., 2008). In the Chinese hamster ovary
cell expression system, PNPO enzyme activity for E50K plus c.[364-
1G4A] and R95H was undetectable and 18% of wild-type, respect-
ively. Why with one or both mutations showing 18% residual activ-
ity, should there be no or minimal response to pyridoxine? One
possibility is that all of these patients were premature and tested
for pyridoxine responsiveness in the first week of life. PNPO tran-
scription is low in the foetus compared to adults (30% adult levels in
liver; 2% adult levels in brain) (Ngo et al., 1998; Kang et al., 2004).
An analysis of B6 vitamers in very preterm infants has shown that
CSF may contain significant amounts of pyridoxine alongside a low
PLP concentration (Albersen et al., 2012). Thus PNPO activity is al-
ready critically low in infants born before 30 weeks. PNPO mutations
can therefore be expected to lead to more severe effects in a preterm
than in a term infant. Further, this may suggest a therapeutic role for
PLP in seizures in preterm infants without PNPO mutations. In add-
ition newborns can develop riboflavin deficiency in the first days of
life (Hovi et al., 1979) and this could further reduce PNPO activity.
Does the maternal supply of B6 to the
developing foetus affect phenotype?
Patient 8, who was in poor condition at birth and started having
seizures 3 h after birth, is homozygous for the sequence variant
R116Q—the same genotype as Patient 7 who was normal until
the age of 5 months. Therefore, whilst a predisposition to B6-re-
sponsive seizures may be determined by the R116Q/R116Q
phenotype, other factors determine whether a child is in poor
condition at birth and develops seizures in the first 24 h. The com-
parison of Patients 3 and 4 (siblings) indicates that the most likely
additional factor is how well the foetus has been supplied with
vitamin B6 by the mother (Schenker et al., 1992). In the case of
Patient 4, the mother took a multivitamin preparation during preg-
nancy (2.6 mg/day of pyridoxine and 1.8 mg/day of riboflavin)
and an additional PLP supplement just before delivery, which ap-
peared to prevent intrauterine seizures and early post-natal seiz-
ures. A recent study suggests that PLP levels in Pakistani adults are
lower than in other ethnic groups (Iqbal et al., 2009). If we look at
the backgrounds of patients born prematurely, and/or those that
had low Apgar scores and/or those that needed resuscitation,
17/21 are from a non-Caucasian background whereas for patients
not meeting these criteria, the figure is only 1 in 8 (Table 4).
Differences in maternal plasma PLP and pyridoxal levels may
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explain the phenotypic differences seen in Patients 7 and 8, both
of whom are homozygous for R116Q.
Prevalence of R116Q variant
The presence of R116Q-decreased PNPO activity by 20% when
compared with wild-type; however, R116Q is listed as a single
nucleotide polymorphism in Ensembl (Supplementary Table 3). It
has been suggested that low PNPO activity in erythrocytes may
confer resistance to malaria (Anderson et al., 1993). A second
enzyme important in maintaining high levels of PLP in the red
cell is pyridoxal kinase. Mean red blood cell pyridoxal kinase ac-
tivity in black Americans is 40% that of white Americans (Chern
and Beutler, 1976) and it has been suggested that this lower ac-
tivity was favoured by natural selection because it conferred re-
sistance to malaria (Martin et al., 1978; Flanagan and Beutler,
2006). Plasmodium produces enzymes for de novo synthesis of
PLP and for phosphorylation of pyridoxal, but it is possible that
erythrocyte schizogony requires some PLP to be provided by the
host. A gene encoding PNPO, and therefore capable of regener-
ating PLP from PMP, has not been convincingly demonstrated in
plasmodium (Mu¨ller and Kappes, 2007). Furthermore, at least one
parasite enzyme that is important in erythrocyte schizogony (or-
nithine decarboxylase) gradually loses activity that can be restored
by the addition of PLP (Bitonti et al., 1987).
Conclusion
Three groups of patients with PNPO mutations that
reduced enzyme activity have been identified: (i) patients with neo-
natal onset seizures responding to PLP; (ii) a patient with infantile
spasms (onset 5 months) responsive to PLP; and (iii) patients with
seizures starting before 3 months of age responding to pyridoxine.
One sequence variant, R116Q, a single nucleotide polymorphism
that has been reported in the general population, was found to
have an effect on PNPO activity. We believe the reduction in
PNPO activity and B6-responsive epilepsy in the patients reported
here indicates that it is a variant that contributes to the pathogen-
esis of epilepsy. It is possible that R116Q is responsible for the
susceptibility locus for genetic generalized epilepsy on 17q21.32
(close to rs72823592). Although additional studies will be neces-
sary to delineate this further, our findings support the use of DNA
tests for PNPO deficiency in a wide range of infants with epilepsy.
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